Prognostic evaluation of catalytic iron in patients with acute coronary syndromes

Clinical Cardiology

Volumn 36, Issue 3, 2013, Pages 139-145

  Steen, Dylan L ^a   Cannon, Christopher P ^a   Lele, Suhas S ^b   Rajapurkar, Mohan M ^c   Mukhopadhyay, Banibrata ^c   Scirica, Benjamin M ^a   Murphy, Sabina A ^a   Morrow, David A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Bhailal Amin General Hospital   (India)

^c MULJIBHAI PATEL UROLOGICAL HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CATALYTIC IRON; IRON; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ADULT; AGE; ARTICLE; BLEEDING; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL EVALUATION; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CREATININE CLEARANCE; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HEART FAILURE; HEART INFARCTION; HUMAN; IRON BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING; ST SEGMENT DEPRESSION;

ACUTE CORONARY SYNDROME; AGED; ANGINA, UNSTABLE; BIOLOGICAL MARKERS; CATALYSIS; FEMALE; HUMANS; INDIA; IRON; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; OXIDATION-REDUCTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REACTIVE OXYGEN SPECIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 84875248115     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22089     Document Type: Article

References (27)

1. Danesh J, Appleby P., Coronary heart disease and iron status: meta-analyses of prospective studies. Circulation. 1999; 99: 852-854.
2. Rajapurkar MM, Shah SV, Lele SS, et al. Association of catalytic iron with cardiovascular disease. Am J Cardiol. 2012; 109: 438-442.
3. Lele S, Shah S, McCullough PA, et al. Serum catalytic iron as a novel biomarker of vascular injury in acute coronary syndromes. EuroIntervention. 2009; 5: 336-342.
4. Cannon CP, McCabe CH, Wilcox RG, et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation. 2000; 102: 149-156.
5. De Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001; 345: 1014-1021.
6. Evans PJ, Halliwell B., Measurement of iron and copper in biological systems: bleomycin and copper-phenanthroline assays. Methods Enzymol. 1994; 233: 82-92.
7. Halliwell B, Gutteridge JM., Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol. 1990; 186: 1-85.
8. O'Donoghue M, de Lemos JA, Morrow DA, et al. Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. Circulation. 2006; 114: 550-557.
9. Sullivan JL., Iron and the sex difference in heart disease risk. Lancet. 1981; 1: 1293-1294.
10. Williams RE, Zweier JL, Flaherty JT., Treatment with deferoxamine during ischemia improves functional and metabolic recovery and reduces reperfusion-induced oxygen radical generation in rabbit hearts. Circulation. 1991; 83: 1006-1014.
11. De Valk B, Marx JJ., Iron, atherosclerosis, and ischemic heart disease. Arch Intern Med. 1999; 159: 1542-1548.
12. Baliga R, Zhang Z, Baliga M, et al. Evidence for cytochrome P-450 as a source of catalytic iron in myoglobinuric acute renal failure. Kidney Int. 1996; 49: 362-369.
13. Paller MS, Jacob HS., Cytochrome P-450 mediates tissue-damaging hydroxyl radical formation during reoxygenation of the kidney. Proc Natl Acad Sci U S A. 1994; 91: 7002-7006.
14. Pepper JR, Mumby S, Gutteridge JM., Transient iron overload with bleomycin-detectable iron present during cardiopulmonary bypass surgery. Free Radic Res. 1994; 21: 53-58.
15. Sengoelge G, Rainer V, Kletzmayr J, et al. Dose-dependent effect of parenteral iron therapy on bleomycin-detectable iron in immune apheresis patients. Kidney Int. 2004; 66: 295-302.
16. Voogd A, Sluiter W, van Eijk HG, et al. Low-molecular-weight iron and the oxygen paradox in isolated rat hearts. J Clin Invest. 1992; 90: 2050-2055.
17. Baliga R, Ueda N, Shah SV., Increase in bleomycin-detectable iron in ischaemia/reperfusion injury to rat kidneys. Biochem J. 1993; 291 (part 3): 901-905.
18. Paraskevaidis IA, Iliodromitis EK, Vlahakos D, et al. Deferoxamine infusion during coronary artery bypass grafting ameliorates lipid peroxidation and protects the myocardium against reperfusion injury: immediate and long-term significance. Eur Heart J. 2005; 26: 263-270.
19. Kirk EA, Heinecke JW, LeBoeuf RC., Iron overload diminishes atherosclerosis in apoE-deficient mice. J Clin Invest. 2001; 107: 1545-1553.
20. Stadler N, Lindner RA, Davies MJ., Direct detection and quantification of transition metal ions in human atherosclerotic plaques: evidence for the presence of elevated levels of iron and copper. Arterioscler Thromb Vasc Biol. 2004; 24: 949-954.
21. Berger TM, Polidori MC, Dabbagh A, et al. Antioxidant activity of vitamin C in iron-overloaded human plasma. J Biol Chem. 1997; 272: 15656-15660.
22. Smith C, Mitchinson MJ, Aruoma OI, et al. Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions. Biochem J. 1992; 286 (part 3): 901-905.
23. Nagy E, Eaton JW, Jeney V, et al. Red cells, hemoglobin, heme, iron, and atherogenesis. Arterioscler Thromb Vasc Biol. 2010; 30: 1347-1353.
24. Yuan XM, Anders WL, Olsson AG, et al. Iron in human atheroma and LDL oxidation by macrophages following erythrophagocytosis. Atherosclerosis. 1996; 124: 61-73.
25. Chevion M, Jiang Y, Har-El R, et al. Copper and iron are mobilized following myocardial ischemia: Possible predictive criteria for tissue injury. Proc Natl Acad Sci U S A. 1993; 90: 1102-1106.
26. Shimpo M, Morrow DA, Weinberg EO, et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation. 2004; 109: 2186-2190.
27. Scirica BM, Morrow DA, Cannon CP, et al. Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. Clin Chem. 2007; 53: 1800-1807.